東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Development of an Anti-Muc1 Antibody...

Coyle, Kelsey R.

FindBook

Google Book

Amazon

博客來

Development of an Anti-Muc1 Antibody-drug Conjugate with Specificity to Target Cancer.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Development of an Anti-Muc1 Antibody-drug Conjugate with Specificity to Target Cancer./
作者:	Coyle, Kelsey R.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
面頁冊數:	46 p.
附註:	Source: Masters Abstracts International, Volume: 80-11.
Contained By:	Masters Abstracts International80-11.
標題:	Pharmacology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13882412
ISBN:	9781392161432

Development of an Anti-Muc1 Antibody-drug Conjugate with Specificity to Target Cancer.
Coyle, Kelsey R.

Development of an Anti-Muc1 Antibody-drug Conjugate with Specificity to Target Cancer. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 46 p.

Source: Masters Abstracts International, Volume: 80-11.

Thesis (M.S.)--The University of Arizona, 2019.

This item must not be sold to any third party vendors.

Ever since Paul Ehrlich, Nobel Prize winner and the founder of chemotherapy, postulated that "magic bullets" can be created and used to fight human disease, scientist have been inspired to develop precise and tailored drugs to target cancer 1. This vision came true with the development of a therapeutic that forms highly specific associations with targeted antigens by Kohler and Milstein in the form of monoclonal antibodies (mAb) 2. Huge advances have been made in the past decade with mAb therapy of cancer to treat many common malignancies with over 206 mAbs studied in clinical trials from 1980 to 2005 2,3. Despite these advances, cancer is still affecting and killing numerous lives every day.The monoclonal antibody therapy for cancer is deemed tailored because it specifically targets antigens expressed on cancer cells. Mucin 1 is a transmembrane mucin that is overexpressed in a number of metastatic epithelial cancers 4,5. Its expression correlates with an aggressive form of disease, poor response to therapy, and poor survival 4. The differences between the antigen in tumor and normal cells in terms of biochemical features, cell distribution, and function 5 provide an opportunity to use antibodies to specifically target and attack Muc1 positive tumor cells. Anti-Muc1 antibodies alone, however, have not proven to be sufficiently cytotoxic to kill tumor cells.Depending on type and stage, current cancer treatments include surgery, radiation, chemotherapy, and immunotherapy. The goal of chemotherapy is to kill the fast-growing cancer cells. However, the drugs are often toxic so that they kill they normal cells in the body, leading to critical side effects. In this project, we aim to combine the high specificity properties of anti-Muc1 antibodies with the highly potent chemotherapeutic agent in order to identify a 'magic bullet' immune-based treatment that produces improved efficacy and leads to the specific destruction of tumor-associated Muc1 cancer cells.

ISBN: 9781392161432Subjects--Topical Terms:

634543
Pharmacology.

Development of an Anti-Muc1 Antibody-drug Conjugate with Specificity to Target Cancer.
LDR:03018nmm a2200313 4500 001 2208917
005 20191025102442.5
008 201008s2019 ||||||||||||||||| ||eng d
020 $a 9781392161432
035 $a (MiAaPQ)AAI13882412
035 $a (MiAaPQ)arizona:17181
035 $a AAI13882412
040 $a MiAaPQ $c MiAaPQ
100 1 $a Coyle, Kelsey R. $3 3435986
245 1 0 $a Development of an Anti-Muc1 Antibody-drug Conjugate with Specificity to Target Cancer.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 46 p.
500 $a Source: Masters Abstracts International, Volume: 80-11.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Won, Youngwook.
502 $a Thesis (M.S.)--The University of Arizona, 2019.
506 $a This item must not be sold to any third party vendors.
520 $a Ever since Paul Ehrlich, Nobel Prize winner and the founder of chemotherapy, postulated that "magic bullets" can be created and used to fight human disease, scientist have been inspired to develop precise and tailored drugs to target cancer 1. This vision came true with the development of a therapeutic that forms highly specific associations with targeted antigens by Kohler and Milstein in the form of monoclonal antibodies (mAb) 2. Huge advances have been made in the past decade with mAb therapy of cancer to treat many common malignancies with over 206 mAbs studied in clinical trials from 1980 to 2005 2,3. Despite these advances, cancer is still affecting and killing numerous lives every day.The monoclonal antibody therapy for cancer is deemed tailored because it specifically targets antigens expressed on cancer cells. Mucin 1 is a transmembrane mucin that is overexpressed in a number of metastatic epithelial cancers 4,5. Its expression correlates with an aggressive form of disease, poor response to therapy, and poor survival 4. The differences between the antigen in tumor and normal cells in terms of biochemical features, cell distribution, and function 5 provide an opportunity to use antibodies to specifically target and attack Muc1 positive tumor cells. Anti-Muc1 antibodies alone, however, have not proven to be sufficiently cytotoxic to kill tumor cells.Depending on type and stage, current cancer treatments include surgery, radiation, chemotherapy, and immunotherapy. The goal of chemotherapy is to kill the fast-growing cancer cells. However, the drugs are often toxic so that they kill they normal cells in the body, leading to critical side effects. In this project, we aim to combine the high specificity properties of anti-Muc1 antibodies with the highly potent chemotherapeutic agent in order to identify a 'magic bullet' immune-based treatment that produces improved efficacy and leads to the specific destruction of tumor-associated Muc1 cancer cells.
590 $a School code: 0009.
650 4 $a Pharmacology. $3 634543
690 $a 0419
710 2 $a The University of Arizona. $b Medical Pharmacology. $3 1682535
773 0 $t Masters Abstracts International $g 80-11.
790 $a 0009
791 $a M.S.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13882412